FDA Mandates New Warning Labels on Ozempic, Wegovy Over Rare Vision Loss Risk

The U.S. Food and Drug Administration announced Monday it will require new warnings on all glucagon-like peptide-1 receptor agonist medications over a potential increased risk for a rare eye condition that can cause permanent vision loss. The mandate affects popular diabetes and weight loss drugs including Ozempic, Wegovy, Mounjaro, Zepbound, and Soliqua. All manufacturers must now update their prescribing information to include specific warnings about the condition called nonarteritic anterior ischemic optic neuropathy, or NAION.

The FDA’s safety communication follows a comprehensive evaluation of clinical trial data, animal studies, and post-marketing reports linked to the entire class of GLP-1 medications. The agency began investigating the possible connection between these widely prescribed drugs and NAION following a 2024 study published in JAMA Ophthalmology that identified an increased risk among patients prescribed semaglutide, the active ingredient in Ozempic and Wegovy. While the FDA acknowledged the study had limitations, it prompted a broader review of existing research and clinical trials across the entire drug class.

NAION occurs when blood flow to the optic nerve becomes reduced or blocked, causing sudden, painless vision loss typically in one eye. Sometimes called an “eye stroke,” the condition currently has no known treatment to reverse the vision loss. Doctors don’t know exactly why NAION happens, though health conditions that may disrupt blood flow to the optic nerve have been linked to increased risk. People with diabetes and obesity already face elevated risk for this optic nerve condition, which complicates the picture since these medications specifically treat those conditions.

Clinical Data Reveals Elevated Risk Rates

The agency’s findings stem from a meta-analysis of 126 clinical trials involving more than 134,000 patients. The comprehensive review identified 15 probable cases of NAION overall, including 10 among GLP-1 users and 5 among placebo recipients. The FDA calculated an incidence rate of 6.4 NAION cases per 100,000 person-years among those taking GLP-1 receptor agonists, compared to 3.8 cases per 100,000 person-years among patients receiving a placebo or non-GLP-1 glucose-lowering medication.

According to the FDA, cases of NAION have been documented across all currently marketed products in the GLP-1 drug class. The agency’s announcement confirmed that manufacturers of medications produced by Novo Nordisk, Eli Lilly, and Sanofi must comply with the new labeling requirements. The decision represents a significant regulatory action affecting millions of Americans who rely on these medications for managing diabetes and obesity.

Manufacturers Respond With Different Positions

“Novo continues to believe the data do not establish a cause-and-effect relationship and we remain confident in the benefit-risk profile of our GLP-1 medicines,” said Liz Skrbkova, who leads U.S. media and stakeholder relations for Novo Nordisk.

Skrbkova added that patient safety remains a top priority for Novo Nordisk, emphasizing the company continues to monitor the safety of its medicines, review new research, and work with health authorities around the world. The manufacturer maintains that available research does not establish that GLP-1 medications cause NAION, though it will comply with the FDA’s new labeling requirements.

Eli Lilly took a more measured approach in its response to the FDA mandate. In a statement, a company spokesperson noted that the FDA’s drug safety communication applies to all medicines with GLP-1 receptor agonist activity and does not reference any findings specific to Lilly medicines. The manufacturer stated it is carefully evaluating the update and will respond to the FDA promptly, without disputing the agency’s findings or defending the safety profile of its medications.

European Labels Already Include Vision Warnings

Warnings that semaglutide may cause NAION “in up to 1 in 10,000 patients” were added to European Wegovy and Ozempic labels in June and are already present on major GLP-1 medications in the United Kingdom, the European Union, Denmark, and Australia. Ozempic labels have been updated several times in the United States in recent years to add side effects like intestinal obstruction, but nothing vision-related appeared until this announcement. The new FDA requirement brings American labeling in line with international standards that have existed for months.

Multiple lawsuits filed in recent years have accused manufacturers Eli Lilly and Novo Nordisk of withholding information about vision loss risks from consumers. These legal actions preceded the FDA’s formal investigation and may have contributed to pressure on regulators to examine the potential connection more thoroughly. Several recent studies beyond the 2024 JAMA Ophthalmology research have found a possible link between GLP-1 medications and the rare but serious eye condition.

New Guidance for Healthcare Providers

Health care providers now receive clear instructions to advise patients to immediately report sudden onset of acute, painless, decreased vision, visual field deficits, or other visual disturbances in one eye. If NAION is suspected, the FDA recommends prompt referral to an ophthalmologist for specialized evaluation and care. The agency emphasizes that early detection and professional assessment remain critical even though no treatment currently exists to reverse the vision loss.

Clinicians must now consider discontinuing the GLP-1 medication in patients who develop NAION, unless the benefits of treatment clearly outweigh the risk, the FDA stated. This guidance places physicians in a challenging position when treating patients with diabetes or severe obesity, conditions that carry their own significant health consequences. Doctors will need to weigh the proven metabolic benefits of these medications against the newly documented but rare risk of permanent vision impairment on a case-by-case basis.

The FDA’s action affects one of the fastest-growing segments of the pharmaceutical market, with GLP-1 drugs generating billions in annual sales and transforming treatment approaches for both diabetes and obesity. The new warning requirement underscores the ongoing need for post-market surveillance of even widely prescribed medications, as rare adverse events may only emerge after millions of patients have received treatment over extended periods.